The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2019 | Is haploidentical the best curative option for sickle cell disease?
Miguel Abboud
• 26 Oct 2019
Miguel Abbout, MD, American University of Beirut, Beirut, Lebanon, evaluates whether haploidentical stem cell transplantation is the best curative option for sickle cell disease at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.
